Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Tuberculosis Clear all
Completed Phase 3 Interventional

The Treatment of Tuberculosis in HIV-Infected Patients

NCT00001033
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Early Phase 1 Interventional Results available

Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

NCT05027958
View directory record Official record
Conditions
Healthy, Latent Tuberculosis Infection (LTBI)
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Recruiting Early Phase 1 Interventional

Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis

NCT07830771
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
[18F]-FAPI-74
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Quality by Maintaining Accurate Problems in the EHR

NCT02596087
View directory record Official record
Conditions
Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
Interventions
Problem List Suggestion
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 5:31 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

NCT05766267
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis Infection
Interventions
Rifabutin, Delamanid, Bedaquiline, Moxifloxacin, Pyrazinamide, Isoniazid, Rifampin, Ethambutol
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 21, 2026, 5:31 PM EDT
Completed No phase listed Observational

A Prospective Patient Registry of Patients Exposed to Bedaquiline

NCT02274389
View directory record Official record
Conditions
Pulmonary Multi-drug Resistant Tuberculosis
Interventions
No Intervention
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

NCT04309656
View directory record Official record
Conditions
Multi-drug Resistant Tuberculosis
Interventions
Pretomanid
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 21, 2026, 5:31 PM EDT
Completed No phase listed Observational

trūFreeze® Spray Cryotherapy Patient Registry

NCT01802203
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Dysplasia, Esophageal Neoplasm, Esophageal Stenosis, Bronchial Neoplasm, Stenosis of Bronchus or Trachea
Interventions
truFreeze Spray Cryotherapy
Device
Lead sponsor
US Endoscopy Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
16
States / cities
La Jolla, California • Denver, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

NCT01599897
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
ID93 + GLA-SE, ID93 alone
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 5:31 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Azacytidine During Anti-tuberculosis Therapy

NCT03941496
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
Azacitidine Injection
Drug
Lead sponsor
Andrew Dinardo
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

New Reusable Mask Design With Superior Filtration and Fit

NCT04826809
View directory record Official record
Conditions
Covid19, Tuberculosis, Respiratory Viral Infection
Interventions
N95 mask, Nordell single E-100 layer mask, Nordell double E-100 layer mask
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Mankato, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 21, 2026, 5:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb

NCT00212550
View directory record Official record
Conditions
Pulmonary TB
Interventions
Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas

NCT00468104
View directory record Official record
Conditions
Pleural Effusion Associated With Pulmonary Infection, Bacterial Pleural Effusion Other Than Tuberculosis
Interventions
Alteplase, Placebo
Drug
Lead sponsor
Midwest Pulmonary and Critical Care
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 21, 2026, 5:31 PM EDT
Completed No phase listed Observational

A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida

NCT02198079
View directory record Official record
Conditions
Cystic Fibrosis, Pediatrics
Interventions
Sputum
Biological
Lead sponsor
University of Miami
Other
Eligibility
Up to 18 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT04865536
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

NCT03748992
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 21, 2026, 5:31 PM EDT
Completed No phase listed Observational

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

NCT01587469
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Cepheid
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

Interferon Gamma for Drug Resistant Tuberculosis

NCT00001407
View directory record Official record
Conditions
Pneumonia, Pulmonary Tuberculosis
Interventions
Interferon Gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

NCT03758612
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 oral suspension, TBI-223 enteric capsule, TBI-223 SR Tablet Prototype 1, TBI-223 SR Tablet Prototype 2, TBI-223 SR Tablet Prototype 3, TBI-223 IR Tablet, Placebo suspension
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 21, 2026, 5:31 PM EDT
Completed No phase listed Observational

Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets

NCT05048485
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Helminthiasis, Malnutrition
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 21, 2026, 5:31 PM EDT